Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: TI2, TechInvestorToo who wrote (3706)	11/15/2000 7:40:47 PM
From: RJMC	Read Replies (1) \| Respond to of 5665

Hey all. Back from Boston and the shareholders meeting. Had the chance to meet many of the posters from the Raging Bull board (LarryMacc, MrHiRoller, Aahem, AGrittle, MG'sMom - and her daughter MG). Fun meeting and a lot of good information. I'll post some of the information that I heard (some of this may be repeat information from what has already been posted on the Raging Bull board). First of all, this stock is going to go through the roof. I don't know when, but I don't think things could be going better. I'm more bullish on this stock than ever. Mitch started off the meeting by presenting the information that is being presented to the various institutional investors. He was meeting that same day with some more investors and had additional meeting scheduled for this week. The information is basically what is already on the web site including discussions on the preclinical results of huC242-DM1 and huN901-DM1. Nothing we hadn't already known about or surmised. In addition, he alluded to a third drug where pre-clinical related information will be coming out in the 1st quarter of next year. He talked about what he could regarding the clinical trials in San Antonio and Chicago. Smith Kline basically dictates what can and cannot be said about the trials. The real efficacy information is will be derived from the Chicago study since the increased dosing will fill the gaps due to the half life of the drug. I believe he said they are currently at the 88 mg/m2 dosage level in the Chicago trial. The current company objective is to significantly increase the pipeline of potential drugs. The potential of Immunogen is absolutely enormous!!! They will be looking for additional targets, antibodies and toxins for conjugation with the antibodies. The question was asked whether there were limitations on what antibodies could be conjugated with DM-1. The answer was that DM-1 can be conjugated with any antibody. However, there is a small percentage of antibodies that are not ingested by the cell and hence the DM-1 will not have an impact (about 5% of the antibodies or so). A very interesting story from the meeting: The Genentech deal took about 4 years from start to finish. Last year Genetech called off the deal saying basically that the data on the drug looks great, but we're not interested. In a last ditch effort, Immunogen negotiated a technology transfer agreement where Genentech provided a small amount of the antibody her-2 to Immunogen. Immunogen took the her2 back to the labs, conjugated it with DM-1 and sent the TAP back to Genentech so they could test it for themselves. Mitch said Genentech was silent for several months, and then next thing they knew, Genentech was knocking on door wanting to close the deal on herceptin as well as the option to use DM-1 with the other antibodies as described in the deals in May. This more than anything else struck me as saying something about what Immunogen really has with the TAP technology. I can't say enough about all the positive information at the meeting. Clearly this company is going places in a big way. Mitch of course couldn't talk about the secondary offering since it is still in the quiet period. I believe the pricing date on the secondary offering is this Friday. From my personal view, any institutions buying in at these levels are getting a screaming deal on this stock. Best wishes to all!!!! Bob M.